Clene cleared for accelerated NDA submission after successful FDA meeting
Clene (NASDAQ:CLNN) reported its first-quarter 2026 financial results on Thursday, highlighting a critical regulatory breakthrough that establishes a clear, accelerated path toward commercialization for its investigational ALS drug, CNM-Au8.




_1400082_640x360_2500045379969-640x360.webp&w=3840&q=75)
_1400065_640x360_2500045379977-640x360.webp&w=3840&q=75)





